Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 5 | 2023 | 138 | 2.200 |
Why?
|
| Coronary Disease | 9 | 2015 | 49 | 1.610 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2020 | 57 | 1.390 |
Why?
|
| Cardiovascular Diseases | 6 | 2020 | 293 | 1.360 |
Why?
|
| Cisplatin | 2 | 2023 | 60 | 1.350 |
Why?
|
| Secondary Prevention | 5 | 2020 | 49 | 1.230 |
Why?
|
| Cardiology | 5 | 2021 | 45 | 1.200 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 240 | 1.160 |
Why?
|
| Cardiac Rehabilitation | 4 | 2021 | 6 | 1.060 |
Why?
|
| Lung Neoplasms | 3 | 2021 | 543 | 1.050 |
Why?
|
| Acrylamides | 2 | 2020 | 3 | 0.810 |
Why?
|
| Aniline Compounds | 2 | 2020 | 29 | 0.800 |
Why?
|
| Heart Failure | 7 | 2021 | 141 | 0.750 |
Why?
|
| Exercise Test | 3 | 2018 | 112 | 0.730 |
Why?
|
| Humans | 38 | 2023 | 23572 | 0.710 |
Why?
|
| Carboplatin | 1 | 2021 | 24 | 0.700 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2021 | 5 | 0.700 |
Why?
|
| Benzimidazoles | 1 | 2021 | 9 | 0.690 |
Why?
|
| Paclitaxel | 1 | 2021 | 49 | 0.690 |
Why?
|
| Standard of Care | 1 | 2020 | 11 | 0.680 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 236 | 0.670 |
Why?
|
| Biological Specimen Banks | 1 | 2019 | 5 | 0.640 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 15 | 0.620 |
Why?
|
| Life Style | 3 | 2019 | 160 | 0.580 |
Why?
|
| Cardiorespiratory Fitness | 1 | 2018 | 15 | 0.580 |
Why?
|
| Lipocalin-2 | 1 | 2018 | 1 | 0.580 |
Why?
|
| Cystatin C | 1 | 2018 | 3 | 0.580 |
Why?
|
| Mutation | 1 | 2019 | 330 | 0.560 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 37 | 0.560 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 199 | 0.550 |
Why?
|
| Apoptosis | 2 | 2022 | 198 | 0.540 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 245 | 0.540 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2017 | 2 | 0.540 |
Why?
|
| Taxoids | 1 | 2017 | 11 | 0.530 |
Why?
|
| ErbB Receptors | 3 | 2023 | 54 | 0.510 |
Why?
|
| Cell Proliferation | 1 | 2017 | 165 | 0.500 |
Why?
|
| Aged | 19 | 2023 | 7586 | 0.500 |
Why?
|
| Neoplasms | 1 | 2018 | 223 | 0.470 |
Why?
|
| Patient Education as Topic | 2 | 2013 | 125 | 0.440 |
Why?
|
| Middle Aged | 16 | 2021 | 8155 | 0.430 |
Why?
|
| Myocardial Ischemia | 1 | 2014 | 44 | 0.430 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 19 | 0.420 |
Why?
|
| Risk Reduction Behavior | 1 | 2013 | 36 | 0.420 |
Why?
|
| Coronary Artery Disease | 2 | 2017 | 124 | 0.400 |
Why?
|
| Male | 18 | 2023 | 12777 | 0.400 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 401 | 0.400 |
Why?
|
| Acute Coronary Syndrome | 3 | 2021 | 10 | 0.390 |
Why?
|
| Depression | 2 | 2015 | 368 | 0.370 |
Why?
|
| Female | 17 | 2021 | 13266 | 0.360 |
Why?
|
| Critical Pathways | 1 | 2011 | 19 | 0.350 |
Why?
|
| Program Evaluation | 3 | 2017 | 114 | 0.350 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2011 | 18 | 0.350 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 267 | 0.330 |
Why?
|
| Prognosis | 4 | 2021 | 749 | 0.320 |
Why?
|
| Chest Pain | 1 | 2009 | 20 | 0.320 |
Why?
|
| Mass Screening | 1 | 2011 | 168 | 0.310 |
Why?
|
| Australia | 8 | 2021 | 23 | 0.310 |
Why?
|
| Models, Statistical | 1 | 2009 | 113 | 0.310 |
Why?
|
| Smartphone | 2 | 2021 | 15 | 0.310 |
Why?
|
| Medication Adherence | 1 | 2009 | 49 | 0.300 |
Why?
|
| Risk Factors | 9 | 2019 | 1997 | 0.300 |
Why?
|
| Exercise Therapy | 2 | 2021 | 85 | 0.290 |
Why?
|
| Young Adult | 4 | 2021 | 1747 | 0.280 |
Why?
|
| Quality of Life | 4 | 2021 | 565 | 0.260 |
Why?
|
| Death, Sudden | 1 | 2006 | 7 | 0.260 |
Why?
|
| Adult | 7 | 2021 | 7178 | 0.230 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2018 | 39 | 0.220 |
Why?
|
| Prospective Studies | 5 | 2018 | 1535 | 0.210 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2023 | 31 | 0.210 |
Why?
|
| Laryngeal Neoplasms | 1 | 2023 | 28 | 0.200 |
Why?
|
| Cetuximab | 1 | 2023 | 5 | 0.200 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 3770 | 0.200 |
Why?
|
| Counseling | 2 | 2017 | 39 | 0.190 |
Why?
|
| Nose Neoplasms | 1 | 2022 | 35 | 0.190 |
Why?
|
| Cell-Derived Microparticles | 1 | 2022 | 5 | 0.190 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2022 | 59 | 0.180 |
Why?
|
| Risk Assessment | 3 | 2019 | 556 | 0.180 |
Why?
|
| Radiosurgery | 1 | 2021 | 32 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 164 | 0.170 |
Why?
|
| Retrospective Studies | 5 | 2023 | 3122 | 0.170 |
Why?
|
| Societies, Medical | 2 | 2020 | 119 | 0.170 |
Why?
|
| Comorbidity | 4 | 2021 | 431 | 0.160 |
Why?
|
| United Kingdom | 1 | 2019 | 41 | 0.160 |
Why?
|
| Treatment Outcome | 5 | 2021 | 3095 | 0.160 |
Why?
|
| Blood Circulation | 1 | 2019 | 1 | 0.160 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 3 | 0.160 |
Why?
|
| Circulating Tumor DNA | 1 | 2019 | 5 | 0.160 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 51 | 0.160 |
Why?
|
| Walking Speed | 1 | 2019 | 34 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 31 | 0.150 |
Why?
|
| Diastole | 1 | 2019 | 28 | 0.150 |
Why?
|
| Waist Circumference | 1 | 2019 | 35 | 0.150 |
Why?
|
| Obesity, Abdominal | 1 | 2019 | 19 | 0.150 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 34 | 0.150 |
Why?
|
| Stroke Volume | 1 | 2019 | 43 | 0.150 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 9 | 0.150 |
Why?
|
| Biomarkers | 2 | 2019 | 482 | 0.150 |
Why?
|
| Infection Control | 1 | 2020 | 169 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 68 | 0.150 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 443 | 0.150 |
Why?
|
| Peptide Fragments | 1 | 2019 | 57 | 0.150 |
Why?
|
| Mouth | 1 | 2018 | 12 | 0.150 |
Why?
|
| American Heart Association | 1 | 2018 | 15 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 79 | 0.150 |
Why?
|
| Pharynx | 1 | 2018 | 11 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 83 | 0.150 |
Why?
|
| Pandemics | 1 | 2020 | 207 | 0.150 |
Why?
|
| Hemorrhage | 1 | 2018 | 75 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 35 | 0.140 |
Why?
|
| Aspirin | 1 | 2018 | 50 | 0.140 |
Why?
|
| Exercise | 1 | 2021 | 400 | 0.140 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 159 | 0.140 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2017 | 4 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2019 | 402 | 0.130 |
Why?
|
| Caspases | 1 | 2017 | 22 | 0.130 |
Why?
|
| Coronary Vessels | 1 | 2017 | 34 | 0.130 |
Why?
|
| Health Behavior | 3 | 2021 | 149 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 128 | 0.130 |
Why?
|
| United States | 3 | 2018 | 1837 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2019 | 403 | 0.130 |
Why?
|
| Blotting, Western | 1 | 2017 | 132 | 0.130 |
Why?
|
| Telephone | 2 | 2014 | 25 | 0.120 |
Why?
|
| Patient Compliance | 3 | 2016 | 146 | 0.120 |
Why?
|
| Biomarkers, Tumor | 1 | 2017 | 201 | 0.120 |
Why?
|
| Calcium | 1 | 2017 | 356 | 0.110 |
Why?
|
| Depressive Disorder | 2 | 2015 | 163 | 0.110 |
Why?
|
| New Zealand | 3 | 2020 | 10 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 146 | 0.090 |
Why?
|
| Affect | 1 | 2011 | 58 | 0.080 |
Why?
|
| Family Practice | 1 | 2009 | 14 | 0.080 |
Why?
|
| Bayes Theorem | 1 | 2009 | 33 | 0.080 |
Why?
|
| Medical Audit | 1 | 2009 | 5 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2009 | 16 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 29 | 0.080 |
Why?
|
| Unnecessary Procedures | 1 | 2009 | 26 | 0.080 |
Why?
|
| Telemedicine | 1 | 2011 | 85 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2009 | 26 | 0.080 |
Why?
|
| Program Development | 1 | 2009 | 49 | 0.080 |
Why?
|
| Electrocardiography | 1 | 2009 | 93 | 0.080 |
Why?
|
| Exercise Tolerance | 2 | 2021 | 30 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 43 | 0.080 |
Why?
|
| Prevalence | 1 | 2009 | 395 | 0.070 |
Why?
|
| Incidence | 2 | 2019 | 644 | 0.060 |
Why?
|
| Myocardial Revascularization | 1 | 2006 | 16 | 0.060 |
Why?
|
| Life Expectancy | 1 | 2006 | 24 | 0.060 |
Why?
|
| Time Factors | 1 | 2009 | 1295 | 0.060 |
Why?
|
| Cholesterol | 2 | 2003 | 57 | 0.060 |
Why?
|
| Survival Rate | 1 | 2006 | 323 | 0.060 |
Why?
|
| Hypercholesterolemia | 2 | 2002 | 20 | 0.060 |
Why?
|
| Printing, Three-Dimensional | 1 | 2023 | 6 | 0.050 |
Why?
|
| Immobilization | 1 | 2023 | 11 | 0.050 |
Why?
|
| Laryngectomy | 1 | 2023 | 16 | 0.050 |
Why?
|
| Neck | 1 | 2023 | 23 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2023 | 32 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2003 | 42 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 48 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2023 | 57 | 0.050 |
Why?
|
| Victoria | 2 | 2019 | 8 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 30 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 7 | 0.050 |
Why?
|
| Anticholesteremic Agents | 1 | 2002 | 14 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 3 | 0.050 |
Why?
|
| Walk Test | 1 | 2021 | 10 | 0.050 |
Why?
|
| Early Medical Intervention | 1 | 2021 | 13 | 0.040 |
Why?
|
| Length of Stay | 1 | 2023 | 305 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 203 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 379 | 0.040 |
Why?
|
| Health Promotion | 1 | 2002 | 139 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2021 | 255 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 85 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2022 | 606 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2019 | 17 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 69 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 127 | 0.040 |
Why?
|
| Echocardiography | 1 | 2019 | 69 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 127 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2018 | 99 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2018 | 132 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 393 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2017 | 18 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 35 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2019 | 176 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 383 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 112 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 245 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 1493 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 648 | 0.030 |
Why?
|
| Disease Management | 1 | 2017 | 101 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 72 | 0.030 |
Why?
|
| Text Messaging | 1 | 2016 | 13 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 90 | 0.030 |
Why?
|
| Independent Living | 1 | 2018 | 225 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 505 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 819 | 0.030 |
Why?
|
| Anxiety | 1 | 2015 | 142 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2019 | 1466 | 0.030 |
Why?
|
| Social Support | 1 | 2015 | 180 | 0.030 |
Why?
|
| Hypolipidemic Agents | 2 | 2003 | 23 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2011 | 22 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2011 | 36 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2011 | 55 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 209 | 0.020 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2006 | 13 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2006 | 31 | 0.020 |
Why?
|
| Aftercare | 1 | 2006 | 22 | 0.020 |
Why?
|
| Physical Examination | 1 | 2006 | 94 | 0.020 |
Why?
|
| Palliative Care | 1 | 2006 | 107 | 0.010 |
Why?
|
| Allied Health Personnel | 1 | 2003 | 7 | 0.010 |
Why?
|
| Nursing Staff, Hospital | 1 | 2003 | 26 | 0.010 |
Why?
|
| Europe | 1 | 2002 | 54 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 126 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 235 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 299 | 0.010 |
Why?
|
| Hypertension | 1 | 2002 | 163 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2002 | 148 | 0.010 |
Why?
|
| Obesity | 1 | 2002 | 294 | 0.010 |
Why?
|